Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
Junxia Hu(First Affiliated Hospital of Zhengzhou University), Qingjiang Chen(First Affiliated Hospital of Zhengzhou University), Xiaohui Lü(Sichuan Agricultural University), Dianbao Zhang(China Medical University), Qing Leng(Anshan Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li(China Medical University), Xinhua Wang(Zhengzhou University), Fei Chen(Wuhan National Laboratory for Optoelectronics), Lei Zhang(Union Hospital), Meng Dong(First Affiliated Hospital of Zhengzhou University), Jingjing Wu(Beijing Tian Tan Hospital), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Ling Li(First Affiliated Hospital of Zhengzhou University), Shuangshuang Guo(First Affiliated Hospital of Guangzhou Medical University), Mengjie Ding(First Affiliated Hospital of Zhengzhou University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Linan Zhu(First Affiliated Hospital of Zhengzhou University), Xin Wang(Hong Kong University of Science and Technology), Meifeng Yin(First Affiliated Hospital of Zhengzhou University)
Cited by 17
Related Papers
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors
|Nature|2011|866
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer
|Cancer Cell|2018|251
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250